Sanofi-Regeneron Dupixent recommended for EU approval by CHMP to treat COPD patients

Paris: Sanofi and Regeneron have announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of Dupixent (dupilumab) in the European Union (EU) as an add-on maintenance treatment in adults with uncontrolled chronic obstructive pulmonary disease (COPD) characterized by raised blood eosinophils. The European Commission is expected to announce a final decision on the Dupixent application in the coming months.

COPD is a respiratory disease that damages the lungs and causes progressive lung function decline and is the fourth leading cause of death worldwide. Symptoms include persistent cough, excessive mucus production and shortness of breath that may impair the ability to perform routine daily activities, which may lead to sleep disturbances, anxiety and depression. COPD is also associated with a significant health and economic burden due to recurrent acute exacerbations that require systemic corticosteroid treatment and/or lead to hospitalization. Smoking and exposure to noxious particles are key risk factors for COPD, but even individuals who quit smoking can still develop or continue having the disease. There have been no new treatment approaches approved for more than a decade.

The positive CHMP opinion is supported by data from the landmark BOREAS and NOTUS phase 3 studies that evaluated the efficacy and safety of Dupixent in adults with uncontrolled COPD with evidence of type 2 inflammation (i.e., blood eosinophils ≥300 cells per μL). All patients were on background maximal standard-of-care inhaled therapy (nearly all on triple therapy). The primary endpoint was met in both studies, showing Dupixent significantly reduced annualized moderate or severe acute COPD exacerbations by up to 34% compared to placebo. Dupixent rapidly and significantly improved lung function compared to placebo, with improvements sustained at 52 weeks. Additionally, Dupixent improved health-related quality of life at 52 weeks (statistically significant in BOREAS and nominally significant in NOTUS) as assessed by the St. George’s Respiratory Questionnaire (SGRQ).

Safety results in both studies were generally consistent with the known safety profile of Dupixent in its approved indications. 

Submissions are also under review with regulatory authorities around the world, including in the U.S. and China. Earlier this year, the U.S. Food and Drug Administration (FDA) accepted for Priority Review the supplemental Biologics License Application for Dupixent as an add-on maintenance treatment in certain adult patients with uncontrolled COPD. The target action date is September 27, 2024.

The use of Dupixent in COPD is investigational and is not yet approved by global regulatory authorities.

Dupixent is a fully human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) pathways and is not an immunosuppressant. The Dupixent development program has shown significant clinical benefit and a decrease in type 2 inflammation in phase 3 studies, establishing that IL-4 and IL-13 are key and central drivers of the type 2 inflammation that plays a major role in multiple related and often co-morbid diseases.

Dupixent has received regulatory approvals in more than 60 countries in one or more indications including certain patients with atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposis (CRSwNP), eosinophilic esophagitis (EoE), prurigo nodularis and chronic spontaneous urticaria (CSU) in different age populations. More than 850,000 patients are being treated with Dupixent globally.

Read also: USFDA requests additional data on Sanofi Dupixent for treating smoker’s lung

Powered by WPeMatico

Medical Bulletin 01/ June / 2024

Here are the top medical news for the day:

Study links better sleep with lower loneliness
A new study to be presented at the SLEEP 2024 annual meeting found that better sleep health was associated with lower levels of loneliness, and this association was stronger among younger adults.
The results were published in the journal SLEEP.
According to the American Academy of Sleep Medicine, sleep is essential to health. The AASM and the Sleep Research Society recommend that adults should sleep seven hours per night on a regular basis to promote optimal health, productivity and daytime alertness.
Better sleep is crucial for overall health because it allows the body to rest, repair, and rejuvenate. Quality sleep supports a strong immune system, helping you fight off illnesses more effectively. It also plays a key role in brain function, enhancing memory, learning, and concentration. Adequate sleep regulates hormones that control hunger and metabolism, which can help maintain a healthy weight. Additionally, good sleep reduces stress and lowers the risk of mental health issues like anxiety and depression.
The study involved 2,297 adults with a mean age of 44 years. Participants completed an online sleep health questionnaire and loneliness scale. The researchers analysed the results using correlation and linear regression analyses along with moderation analyses.
Results indicate that better sleep health was associated with significantly lower total loneliness, emotional loneliness and social loneliness. While better sleep health was associated with lower total and emotional loneliness across ages, this association was stronger for younger adults. However, age did not moderate the association between sleep health and social loneliness.
“Loneliness is an urgent public health crisis, and there is a pressing need for providers to better understand and treat it. Our results highlight the important role that sleep plays in understanding loneliness across the adult lifespan. Perhaps efforts to improve sleep health could have a beneficial effect on loneliness, especially for young people,” said lead author and principal investigator Joseph Dzierzewski.
Reference: Spencer Nielson, Julia Boyle, Joseph Dzierzewski, 0746 Rested and Connected: An Exploration of Sleep Health and Loneliness Across the Adult Lifespan, Sleep, Volume 47, Issue Supplement_1, May 2024, Pages A319–A320, https://doi.org/10.1093/sleep/zsae067.0746
Only 28% of Indians Consume Healthy Foods, 38% Opt for Fried and Processed Snacks, Reports reveal
The International Food Policy Research Institute (IFPRI) released its Global Food Policy Report 2024: Food Systems for Healthy Diets and Nutrition on May 29, raising serious concerns about the dietary habits in India. The report highlights a significant shift towards unhealthy food consumption, overshadowing the intake of nutritious options.
According to the report, “more people in India consume unhealthy foods such as salty or fried snacks, compared to those consuming vegetables, fruits, and other micronutrient-rich foods.” This shift has led to 16.6 percent of the country’s population suffering from malnutrition, a rise from 15.4 percent in 2011. The prevalence of overweight adults has also increased from 12.9 percent in 2006 to 16.4 percent in 2016.
At least 38 percent of the Indian population eats unhealthy foods, while only 28 percent consume all five recommended food groups, which include a starchy staple, a vegetable, a fruit, a pulse, nut or seed, and an animal-source food. This preference for calorie-dense and nutrient-poor foods is not only high but also growing, leading to an increase in both undernutrition and diet-related non-communicable diseases (NCDs) such as obesity.
The report underscored the rising consumption of processed foods in India and other South Asian countries. These include chocolates, sugar confectioneries, salty snacks, beverages, ready-made convenience foods, and breakfast cereals. After cereals and milk, snacks and prepared foods now account for a major part of Indian food budgets. “The share of packaged (highly processed and calorie-dense) foods in household food budgets nearly doubled during this period, to 12 percent from 6.5 percent,” the report states.
The Indian Council of Medical Research (ICMR) recently issued dietary guidelines warning that “information presented on packaged food can be misleading.” Among its 17 guidelines, ICMR advises consumers to read food labels carefully and minimize the consumption of high-fat, sugar, salt, and ultra-processed foods.
The report, co-authored by 41 researchers from IFPRI and partner organizations, calls for urgent action to transform global food systems. “The 2024 GFPR serves as a clarion call for prioritizing sustainable, healthy diets as a cornerstone of public health and sustainable development,” said Johan Swinnen, director general of IFPRI.
Deanna Olney, director of IFPRI’s nutrition, diets, and health unit, emphasized the critical need for dietary improvements, stating, “Evidence suggests that poor quality diets are the leading cause of disease worldwide and that one in five lives could be saved by improving diets.”
The report urged a comprehensive approach to ensure equitable access to sustainable, healthy diets, highlighting the necessity of addressing all forms of malnutrition and diet-related diseases through improved dietary practices.
Reference: International Food Policy Research Institute. 2024. Global food policy report 2024: Food systems for healthy diets and nutrition. Washington, DC: International Food Policy Research Institute.
Too Much Exercise Linked to Increased Hot Flashes, Study Shows
Hot flashes affect about 80% of women during the years around menopause. Despite their prevalence and extensive research into their causes, much about them remains unknown.
A new study, published in the journal Menopause, the journal of The Menopause Society, suggested that acute changes in physical activity, temperature, and humidity may play a role in the hot flash experience.
Hot flashes, affecting about 80% of women around menopause, are sudden heat events involving increased heat transfer to the skin and sweating. They result from reduced estradiol levels, affecting the hypothalamus that controls body temperature. While physical activity offers many health benefits, it can raise body temperature and potentially trigger hot flashes.
The frequency and intensity of hot flashes can vary widely among women. Some may experience them several times a day, while others may have them less frequently. Hot flashes can be particularly disruptive at night, leading to sleep disturbances and contributing to restlessness and fatigue.
Studies have shown that women with a history of hot flashes often experience them during exercise, unlike asymptomatic women. Recent research indicates that more moderate physical activity correlates with more reported hot flashes.
In the study, researchers involved nearly 200 participants across the three menopause stages (premenopause, perimenopause, and postmenopause).
Data indicated significantly higher odds of acute increases in physical activity preceding both objective and subjective hot flashes during waking and sleeping periods. Additionally, restlessness and increased microclimate temperature at night may precede hot flashes, suggesting that certain behavioural measures, such as using lighter blankets and fans, may be beneficial.
“This study shows a link between increases in physical activity and subsequent subjective and objective hot flashes during both waking and sleeping periods. Clinicians may advise patients of this link while acknowledging the multiple well-known benefits of physical activity. Because temperature during sleep affected the odds of having a hot flash, modifications such as the use of lighter-weight blankets and sleepwear, as well as keeping the room temperature cooler, may help with nighttime hot flashes,” said Dr. Stephanie Faubion, medical director for The Menopause Society.
Reference: Witkowski, Sarah PhD1; White, Quinn BA2; Shreyer, Sofiya MA3; Garcia, Randi L. PhD2; Brown, Daniel E. PhD4; Sievert, Lynnette Leidy PhD3. Acute increases in physical activity and temperature are associated with hot flash experience in midlife women. Menopause ():10.1097/GME.0000000000002373, May 28, 2024. | DOI: 10.1097/GME.0000000000002373

Powered by WPeMatico

AIIMS Bhatinda Invites Applications For Post-Doctoral Fellowship Courses July 2024, know all admission details

Bhatinda- All India Institute of Medical Sciences (AIIMS) Bathinda has invited online applications for Post-Doctoral Fellowship courses commencing from July 2024. Interested candidates have to fill out the application form for Post-Doctoral Fellowship courses by registering through the link mentioned in the advertisement.

The last date to fill out the application form is 15 June 2024 till 5:00 pm. It is strictly instructed that no candidate should register more than one application for the said course.

However, the exam date will be informed separately, and hence candidates are advised to visit the official website of AIIMS Bathinda for the latest updates.

To avoid any discrepancy while applying for Post-Doctoral Fellowship courses for July 2024, AIIMS Bathinda has also released an advertisement detailing the educational qualification, application fee, course fee and other important information.

POST-DOCTORAL FELLOWSHIP COURSES

S.NO

NAME OF THE PROGRAM WITH DEPARTMENT

DURATION

SEAT

1

Post-Doctoral Fellowship in Neuro Anaesthesia by the Department of Anaesthesiology & Critical Care.

01 Year

01 Seat

2

Post-Doctoral Fellowship in Pain Medicine by the Department of Anaesthesiology & Critical Care.

01 Year

01 Seat

3

Post-Doctoral Fellowship in Critical Care Medicine by the Department of Anaesthesiology & Critical Care (Sponsored).

01 Year

01 Seat

4

Post-Doctoral Fellowship in Thoracic Imaging by the Department of Radiodiagnosis.

01 Year

01 Seat

5

Post-Doctoral Fellowship in Diagnostic Neuro Radiology by the Department of Radiodiagnosis.

01 Year

01 Seat

6

Post-Doctoral Fellowship in Abdominal imaging by Department of Radiodiagnosis (Sponsored).

01 Year

01 Seat

7

Post-Doctoral Fellowship in Arthroscopy by the Department of Orthopaedics.

01 Year

01 Seat

8

Post-Doctoral Fellowship in Trauma by the Department of Orthopaedics.

01 Year

01 Seat

9

Post-Doctoral Fellowship in Joint Replacement by the Department of Orthopaedics (Sponsored).

01 Year

01 Seat

APPLICATION FEE

1 For PwBD Candidate: NIL.

2 General/EWS/ OBC category: ₹ 1,000/- + transaction charges as applicable.

3 SC/ST category: ₹ 800/- + transaction charges as applicable

However, candidates can pay the fee through NEFT in the Account given below. The transaction reference number and the date of the transaction should be mentioned in the application form.

Name of Bank.

STATE BANK OF INDIA.

Branch.

MILK PLANT BRANCH BATHINDA.

Name of Account Holder.

EXECUTIVE DIRECTOR AIIMS BATHINDA (HR).

Account No.

40205094104 (2nd, 4th,6th and 10th character is zero).

IFSC.

SBIN0050872 (5th,6th and 8th character is zero).

MICR code.

151002031 (4th,5th and 7th character is zero).

Type of Account.

Current Account.

It is to be noted that payment should be made online only, and the application fee once deposited will not be refunded.

EDUCATION QUALIFICATIONS

S.NO

PROGRAM TYPE

ELIGIBILITY FOR COURSE

1

Post-Doctoral Fellowship in Neuro Anaesthesia.

MD/DNBᵇ in Anaesthesiology from an MCI/NMC recognized Institution.

2

Post-Doctoral Fellowship in Pain Medicine.

MD/DNBᵇ in Anaesthesiology from an MCI/NMC recognized Institution.

3

Post-Doctoral Fellowship in Critical Care Medicine.

MD/DNBᵇ in Anaesthesiology from an MCI/NMC recognized Institution.

4

Post-Doctoral Fellowship in Thoracic Imaging.

MD/DNBᵇ in Radiology/Radiodiagnosis from an MCI/NMC recognized Institution.

5

Post-Doctoral Fellowship in Diagnostic Neuro Radiology.

MD/DNBᵇ in Radiology/Radiodiagnosis from an MCI/NMC recognized Institution.

6

Post-Doctoral Fellowship in Abdominal Imaging.

MD/DNBᵇ in Radiology/Radiodiagnosis from an MCI/NMC recognized Institution.

7

Post-Doctoral Fellowship in Arthroscopy.

MS/DNBᵇ in Orthopaedics from an MCI / NMC recognized Institution.

8

Post-Doctoral Fellowship in Trauma.

MS/DNBᵇ in Orthopaedics from an MCI / NMC recognized Institution.

9

Post-Doctoral Fellowship in Joint Replacement.

MS/DNBᵇ in Orthopaedics from an MCI / NMC recognized Institution.

AGE-LIMIT

There is no upper age limit to apply for this Post-Doctoral Fellowship course. (In-service candidates will have to apply through the proper channels and submit a “No Objection Certificate” NOC from their employer along with their application forms. All eligible candidates seeking admission (Including in service) will have to appear in the entrance examination and go through the process of selection as envisaged for all).

COURSE FEES

The selected candidate will have to pay ₹ 50,000/- per year for the course one time.

METHOD OF SELECTION

The application of the candidates who will be received within the prescribed date and time and who submit the requisite fee will be scrutinised by the scrutiny committee of the Institute, and only the eligible candidates will be called for personal interview before the Selection Committee of the Institute. However, the same would be provisional subject to fulfilling all requirements, failing which he/she will not be allowed to appear for an interview. In case the number of applicants is large, the selection committee of the Institute may devise criteria for short-listing the candidates, which may include holding a written examination.

DOCUMENTS

The Candidate should bring the following original documents and one set of self-attested photocopies at the time of the Interview with the application form-

1 Identity Proof (PAN Card, Passport, Driving License, Voter Card etc.).

2 Address Proof (Ration Card, Passport, Driving License, Aadhar Card etc.).

3 Certificate showing Date of Birth. (10th Certificate/Birth Certificate).

4 Class 10th & 12th Marksheets & Certificates.

5 MBBS and MD/DNB*/MS/M.Ch Marksheets & Certificates.

6 FMGE Certificate conducted by NBE (For Foreign Graduate – MBBS).

7 Attempt Certificate.

8 Internship Completion Certificate.

9 Registration with Medical Council of India/ State Medical Council.

10 Experience Certificate.

11 No Objection Certificate (In case of working in Govt. sector).

12 Publications.

13 Any other relevant documents.

PAY SCALE

₹18,750 + 6,600 (Grade Pay) + NPA (Non-Practicing Allowance) plus other usual allowance or revised pay scale as per 7th CPC as applicable (Level – 11 of the Matrix (Pre-revised PB – 3, entry pay of the ₹ 67,700/- per month + NPA plus other usual allowance admissible under rules).

The candidates must have completed the requisite qualification, degree, and tenure by 28 February 2024. The candidates who are likely to complete their requisite qualification, degree, and tenure after 28 February 2024 will not be eligible to appear in this examination.

BOND

Candidates selected for Post-Doctoral Fellowship will execute a bond of ₹ 2,00,000/- on a Non-Judicial Stamp Paper of ₹ 100/- along with 2 sureties.

IMPORTANT POINTS

1 Candidates who are permanent employees of any Central/State Government/Armed Forces or the Public Sector Undertaking/Autonomous Body can be sponsored by the respective Government/Defence Authorities or the Competent Authorities of the PSU/Autonomous Body.

2 A State Government can sponsor candidates only for those Fellowship programs which are not available in the State. A certificate regarding non-availability of the Fellowship (for which the candidate is being sponsored) in the concerned State, duly signed by the Secretary/Director General of Health Services of the Central / State Government/ DGAFMS/Competent Authority or PSU/Autonomous Body viz. The Director/Executive Head of the concerned organisation should be furnished in the format prescribed for this purpose.

3 All eligible “sponsored” candidates will be called by the Institute for an entrance test.

4 Seats, as shown in the prospectus, are available for “sponsored” candidates. Sponsored candidates will be designated as “Fellow”.

5 The subject for which the candidate is being sponsored should be clearly specified in the sponsorship form by the sponsoring authority. The candidate can be sponsored for only one subject. The applications of those candidates who are sponsored for more than one subject will not be considered.

6 No “Sponsored” candidate will not pay any emoluments to the Institute during the training period. Such payments will be the responsibility of the sponsoring authority (i.e. Central/State Government or Defense Authorities).

7 Those candidates who have undergone DNB training in an institution which now runs MCI-recognised postgraduate degree courses in a given subject, their DNB qualifications shall be considered at par with MCI-recognised qualifications in that subject only.

8 Those candidates who have three years of teaching experience in the subject as Resident/Registrar/Demonstrator/ Tutor / or work experience gained during DNB training in both Broad Specialities and Super-Specialities courses in other locations/institutions (100 or more bedded hospitals) shall work for one additional year as a senior resident in an MCI recognized/permitted institution for equivalence with MD/MS/DM/M.Ch.

9 Those candidates who have three years of teaching experience in the subject as Resident/Registrar/Demonstrator/ Tutor / or work experience gained during DNB training or after possessing DNB qualification, in both Broad Specialities and Super Specialities course from an institution not covered in sub-clauses (a) to (c) shall work for two additional years as Sr. Resident/Research Associate (CSIR) in an MCI recognised/permitted medical college/institution for equivalence with MD/MS/DM/M.Ch.

To view the advertisement, click the link below

Powered by WPeMatico

Pune doctor attacked with iron stand for alleged delay in dressing wound

Pune: In an incidence of violence against medical professionals, a 57-year-old doctor at a private clinic in Vaiduwadi was attacked by a patient with an iron stand over an alleged delay in dressing his wound. In response, the police have booked the patient.   

In addition to the doctor being attacked, two female employees at the clinic were also allegedly mistreated by the patient who came to have the wound on his right hand treated. However, he became aggressive towards the staff members when he discovered that the doctor was absent from the clinic.

After reaching the clinic, the doctor identified as Prakash Gunjal was allegedly attacked by the iron stand that the patient had picked up from the neighbouring garage. However, it narrowly missed him and the doctor sustained only minor injuries.

Also read- Telangana Doctor Attacked & Suspended! Medical Fraternity Boycott Duties Demanding Suspension Revocation, Action Against Culprits

As per a TOI news report, the incident happened on May 27 around 6.30 pm when the doctor asked the patient to leave and come the next day after he abused and used foul language to the female employees. 

According to the police, the patient walked out and hurled a stone at the clinic following which the attack took place. Based on the doctor’s complaint, the patient was booked on Tuesday and a notice has been issued to him for an appearance at the police station for questioning. 

Speaking to The Daily, the doctor said, “The patient, a driver by profession, reached the clinic to dress his wound on his right hand he had received in an accident. He picked up a dispute with my staffers and abused them in foul language after not finding me present in the clinic.”  

Further, he added, “I sought reasons from the patient over his misbehaviour as soon as I reached the clinic. I told him to leave immediately and come back the following day to dress the wound. He then picked up an iron stand from a neighbouring garage and attacked me on my head. Fortunately, it grazed past, and I escaped with minor scratches. Passers-by caught hold of the patient and thrashed him. He was later handed over to the police.”

Inspector (crime) Mangal Modhawe told The Daily, “We have issued a notice to the patient telling him to join police in the investigation as he was booked under bailable offences. On the basis of the outcome of his questioning, a call to arrest him will be taken at a later stage.”

Also read- On-Duty Doctor Allegedly Thrashed By Patient’s Kin At Bhima Bhoi Medical College

Powered by WPeMatico

Johnson & Johnson Executive Vice President William N Hait to retire

New Brunswick: Johnson & Johnson has announced that William N. (Bill) Hait, M.D., Ph.D., will retire from his position as Executive Vice President, Chief External Innovation and Medical Officer, in September of this year.

Since joining Johnson & Johnson in 2007, Dr. Hait has focused his teams on the intersection of unmet medical need and breakthrough science, transforming the lives of millions of patients around the world. In his current role as Chief External Innovation and Medical Officer, Dr. Hait has led the Company’s efforts to tap the external innovation ecosystem for disruptive technologies and cutting-edge science that is helping its sectors improve human health while advancing how Johnson & Johnson meets its obligations around product safety and ethical research.

“From his leadership of what now is our Innovative Medicine R&D Organization to his current role, Bill has been pivotal to advancing how Johnson & Johnson combines transformative innovation with a relentless focus on patient care to improve human health, aligned with Our Credo,” said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. “I’ve had the pleasure, and privilege, of working with Bill for many years and have benefited personally from his wisdom, his relentless pursuit of innovation, and his passion to improve the health of patients everywhere. In addition, his remarkable track record of developing and nurturing talented leaders across our company will leave a legacy that will benefit us, and patients, for many years to come.”

Dr. Hait joined Johnson & Johnson to launch what became the Company’s Innovative Medicine Oncology Therapeutic Area, serving as its first Global Therapeutic Area Head from 2009 to 2011. Under his leadership as Global Head of Innovative Medicine R&D from 2011 – 2018, and more recently as Interim Head between 2022 – 2023, the Company’s Innovative Medicine sector launched more than 20 new products, including DARZALEX (daratumumab), ERLEADA (apalutamide), IMBRUVICA (ibrutinib), SPRAVATO (esketamine), TREMFYA (guselkumab), and ZYTIGA (abiraterone acetate), transforming the lives of millions of people.

Prior to Johnson & Johnson, Bill was the founding director of the Rutgers Cancer Institute of New Jersey, New Jersey’s first and only National Cancer Institute-designated comprehensive cancer center. He also served as Professor of Medicine and Pharmacology and Associate Dean for Oncology Programs at the University of Medicine and Dentistry of New Jersey – Robert Wood Johnson Medical School. Previously, he was the Chief of the Division of Medical Oncology at the Yale University School of Medicine. He graduated from the University of Pennsylvania and earned an M.D. and Ph.D., cum laude, from the Medical College of Pennsylvania.

Read also: JnJ to buy rights to Numab Therapeutics Clinical-Stage Bispecific Antibody NM26

Powered by WPeMatico

Molecular profiling found to improve diagnosis and survival for children with high risk cancers

Cancer is the leading cause of disease-related death in children in most developed countries, and at least a quarter of these patients are diagnosed with aggressive high-risk or relapsed cancers, with an expected five-year survival rate of less than 30%. Accurate diagnosis can be difficult, and survivors often suffer life-long side effects because of the toxic treatments needed to cure them.

Powered by WPeMatico

Polygenic risk scores give inaccurate and highly inconsistent results in embryo selection, researchers find

Polygenic risk scores (PRSs) are estimates of an individual’s susceptibility to a specific complex trait obtained by aggregating the effects of dozens, thousands, and potentially millions of genetic variants associated with that specific trait into a single figure. Some private companies now market PRS embryo screening to prospective parents through the use of in vitro fertilization and pre-implantation genetic testing.

Powered by WPeMatico

Eye-tracking techniques could help primary care providers diagnose autism sooner, more accurately

Nearly 3% of all children in the United States are diagnosed with autism, according to the Centers for Disease Control and Prevention. But a collaborative team of researchers at Indiana University and Purdue University are finding ways to make the right diagnosis sooner.

Powered by WPeMatico

Novel CAR T therapy and shorter targeted therapy durations show promise for patients with leukemia

Researchers from The University of Texas MD Anderson Cancer Center presented positive clinical results from two studies today at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.

Powered by WPeMatico

This self-powered sensor could make MRIs more efficient

MRI scans are commonly used to diagnose a variety of conditions, anything from liver disease to brain tumors. But, as anyone who has been through one knows, patients must remain completely still to avoid blurring the images and requiring a new scan. A prototype device described in ACS Sensors could change that. The self-powered sensor detects movement and shuts down an MRI scan in real time, improving the process for patients and technicians.

Powered by WPeMatico